Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor losses may be recovered under federal securities laws.What if I purchased Zevra securities?If you purchased Zevra securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.There is no cost or obligation to you.Background of the investigationOn August 12, 2025, Zevra disclosed its second-quarter 2025 financial results and reported, among other things, an $11.7 million inventory write-down. Following this disclosure, Zevra’s share price declined by approximately 25%.On November 20, 2025, Zevra announced the resignation of its Chief Financial Officer. Following this announcement, Zevra’s stock price declined approximat
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™GlobeNewswire
- Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026GlobeNewswire
- Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™GlobeNewswire
ZVRA
Earnings
- 11/5/25 - Beat
ZVRA
Sec Filings
- 2/10/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- ZVRA's page on the SEC website